Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stake Boosted by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,004 shares of the company's stock after acquiring an additional 17,451 shares during the period. Wells Fargo & Company MN owned about 0.15% of Tarsus Pharmaceuticals worth $3,156,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of TARS. Thoroughbred Financial Services LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $262,000. Geode Capital Management LLC boosted its position in Tarsus Pharmaceuticals by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 838,804 shares of the company's stock worth $46,456,000 after acquiring an additional 3,014 shares during the last quarter. AIGH Capital Management LLC raised its holdings in Tarsus Pharmaceuticals by 9.9% in the 4th quarter. AIGH Capital Management LLC now owns 224,713 shares of the company's stock valued at $12,442,000 after acquiring an additional 20,300 shares during the last quarter. Pictet Asset Management Holding SA purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $284,000. Finally, Blair William & Co. IL acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $1,508,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 0.1 %

Tarsus Pharmaceuticals stock traded up $0.03 during trading on Friday, reaching $50.00. 754,503 shares of the company's stock were exchanged, compared to its average volume of 689,977. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -13.12 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company's 50-day moving average is $47.60 and its two-hundred day moving average is $48.34.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The business had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. On average, analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares of the company's stock, valued at $2,349,263.79. This represents a 4.36 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $154,539.24. Following the sale, the general counsel now directly owns 51,712 shares in the company, valued at approximately $2,591,288.32. The trade was a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 32,542 shares of company stock valued at $1,581,173. Corporate insiders own 8.25% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on TARS shares. Oppenheimer increased their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Barclays cut their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Guggenheim restated a "buy" rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.